0001654954-22-014266.txt : 20221026
0001654954-22-014266.hdr.sgml : 20221026
20221026214836
ACCESSION NUMBER: 0001654954-22-014266
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221024
FILED AS OF DATE: 20221026
DATE AS OF CHANGE: 20221026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wu Hui-Lan
CENTRAL INDEX KEY: 0001901988
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41461
FILM NUMBER: 221334668
MAIL ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ainos, Inc.
CENTRAL INDEX KEY: 0001014763
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 751974352
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 858-869-2986
MAIL ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
FORMER COMPANY:
FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC
DATE OF NAME CHANGE: 19960516
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2022-10-24
0001014763
Ainos, Inc.
AIMD
0001901988
Wu Hui-Lan
8880 RIO SAN DIEGO DRIVE, SUITE 800
SAN DIEGO
CA
92108
false
true
false
false
Chief Financial Officer
Common Stock
2022-08-09
4
A
false
14705
3.40
A
18905
I
Daughter
Common Stock
2022-10-24
4
A
false
133333
1.89
A
144533
D
RSU
1.89
2022-10-24
4
C
false
2000000
1.89
D
2022-09-30
COMMON
133333
0
D
RSU
2022-10-24
4
A
false
35000
A
COMMON
35000
35000
D
Yun-Huan Liao is Hui-Lan Wu's daughter
Reference is made to that certain Convertible Note Purchase Agreement and Convertible Promissory Note ("Note") in the principal amount of $50,000 between the Issuer and the Reporting Person's daughter, Yu-Huan Liao. The Note bears no interest, matures on March 30, 2027, and is subject to mandatory conversion at a conversion price of 80% of an initial property offering price (if the Issuer conducts an initial public offering). On 08/11/22, the Company completed a public offering at a $4.25 per unit price ("Offering") and a 15-for-1 reverse stock split on 08/08/22 ("Reverse Split"). Transaction reflects an acquisition price of $3.40 per share (80% of the Offering) and the 14,705 issued shares give effect to the Reverse Split.
This reported transaction represents the settlement of 2,000,000 RSUs adjusted to 133,333 common stock after giving effect the Reverse Stock Split
This reported transaction represents the conversion of 2,000,000 Restricted Stock Units (the "RSUs") adjusted to 133,333 shares giving effect to the Reverse Stock Split. The RSUs were originally granted pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") under the Company's 2021 Stock Incentive Plan. The converted shares underlying the RSUs vested on September 30, 2022 and are may not be sold within 6 months of the grant date.
This reported transaction represents the granting of 35,000 Restricted Stock Units (the "RSUs"). The RSUs were originally authorized pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") and under the Company's 2021 Stock Incentive Plan. The RSUs will vest in increments of 15% on 4/24/23 and 10/24/23, 30% on 10/24/24 and 40% on 10/24/25, subject to normal and customary termination events.
N/A
/s/ John Junyong Lee POA for Hui-Lan Wu
2022-10-26